Brief: Clearpoint Neuro And UCB Enter License Agreement For Gene Therapy Drug Delivery
May 24 (Reuters) - Clearpoint Neuro Inc CLPT.O :
* CLEARPOINT NEURO AND UCB ENTER LICENSE AGREEMENT FOR GENE
THERAPY DRUG DELIVERY
* CLEARPOINT NEURO INC - FURTHER FINANCIAL DETAILS OF
AGREEMENT
WERE NOT DISCLOSED
* CLEARPOINT NEURO INC- UCB TO UTILIZE CO'S PROPRIETARY
TECHNOLOG,
SERVICES IN CONNECTION WITH DEVELOPMENT OF UCB'S GENE THERAPY
PRODUCTS
Source text for Eikon: ID:nGNEbpRknX
Further company coverage: CLPT.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Clearpoint Neuro
See all newsClearpoint Neuro Inc reports results for the quarter ended June 30 - Earnings Summary
ClearPoint Neuro Q2 revenue rises 18% but misses estimates
Brief: ClearPoint Neuro Q2 Revenue USD 10.9 Million
ClearPoint Neuro Q1 revenue rises 43%, beats estimates
ClearPoint Neuro Q4 revenue rises on IRRAS acquisition